Crystalline anti-human IL-12 antibodies
AssigneeAbbVie Inc.
InventorsDavid W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
Life of this patent
Estimating the term…
Abstract
The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
Claims19
A crystal of an anti-human IL-12 antibody comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:
- 2, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:
- 1, and wherein said crystal has a length of about 2-500 μm.
A method of treating an IL-12-related disorder in a subject, which method comprises administering to said subject a therapeutically effective amount of a crystal of an anti-human IL-12 antibody, comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:
- 2, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:
- 1, and wherein said crystal has a length of about 2-500 μm, thereby treating said subject.
A method for treating a mammal comprising the step of administering to the mammal an effective amount of a crystal of an anti-human IL-12 antibody, comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:
- 2, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:
- 1, and wherein said crystal has a length of about 2-500 μm, thereby treating said mammal.
Dependencies are inferred from the claim text.